The neurochemistry of pain is a delicate balance between excitatory signals that drive nociception and inhibitory signals that provide analgesia. These neurotransmitters are the molecular targets for almost every pharmacological intervention, from the NMDA-antagonism of Ketamine to the GABA-ergic effects of Baclofen.

---

1. Excitatory Neurotransmitters: The “Go” Signals

These chemicals are released by primary afferent fibers in the dorsal horn to propagate the pain signal toward the brain.

I. Glutamate: The Essential Driver

Glutamate is the primary excitatory neurotransmitter in the entire Central Nervous System (CNS) and is the main chemical released by A-delta and C-fibers at their first synapse.

• AMPA Receptors: Responsible for “fast” synaptic transmission. They mediate the initial, acute pain signal.
• NMDA Receptors: The “master switch” for chronic pain. As discussed in our Central Sensitization article, these are normally blocked by magnesium and only activate during sustained, high-frequency pain.
• Clinical Significance: Blocking the NMDA receptor (via Ketamine or Memantine) is a key strategy for “resetting” a sensitized nervous system.

II. Substance P: The Neuropeptide of Intensity

Substance P is a neuropeptide released primarily by C-fibers.

• Role: It facilitates the action of glutamate, essentially “turning up the volume” of the pain signal. It is also involved in neurogenic inflammation when released peripherally.
• NK-1 Receptors: Substance P binds to Neurokinin-1 (NK-1) receptors in the dorsal horn.
• Clinical Significance: While many drugs have tried to target Substance P directly, its most famous clinical correlation is Capsaicin, which causes a massive release and subsequent depletion of Substance P, leading to long-term desensitization.

III. CGRP (Calcitonin Gene-Related Peptide)

CGRP is a potent vasodilator and a key player in the transmission of pain, particularly in the trigeminal system.

• Clinical Significance: CGRP is the primary target for modern migraine treatments (CGRP antagonists or “Gepants”).

---

2. Inhibitory Neurotransmitters: The “Stop” Signals

These chemicals act as the “brakes” of the nervous system, typically by hyperpolarizing the neuron (making it harder to fire).

I. GABA (Gamma-Aminobutyric Acid)

GABA is the chief inhibitory neurotransmitter in the CNS. In the dorsal horn, GABAergic interneurons “gate” the incoming pain signals.

• GABA-A Receptors: Ionotropic receptors that open chloride channels, causing rapid inhibition. (Target of Benzodiazepines).
• GABA-B Receptors: Metabotropic receptors that inhibit calcium entry or increase potassium exit.
• Clinical Significance: Baclofen is a potent GABA-B agonist used to treat spasticity and certain types of neuropathic pain (like Trigeminal Neuralgia).

II. Glycine

Glycine is the primary inhibitory neurotransmitter in the spinal cord.

• Role: Like GABA, it provides “tonic” inhibition to the dorsal horn.
• Clinical Significance: Loss of glycinergic inhibition is thought to be a major contributor to the development of allodynia.

III. Endogenous Opioids (Enkephalins, Endorphins, Dynorphins)

The body’s natural “painkillers” produced in the PAG and the dorsal horn.

• Role: They bind to Mu, Kappa, and Delta receptors to inhibit the release of Substance P and Glutamate.
• Clinical Significance: Exogenous opioids (Morphine, Fentanyl) mimic this natural system but carry the risk of down-regulation (tolerance) and hyperalgesia.

---

3. The Modulators: Serotonin and Norepinephrine

As discussed in the “Descending Pathways” article, these monoamines play a dual role.

• Norepinephrine (NE): Almost exclusively inhibitory in the spinal cord via alpha2-adrenergic receptors.
• Serotonin (5-HT): Can be inhibitory (via 5-HT1 receptors) or facilitatory (via 5-HT2 and 5-HT3 receptors).
• Clinical Significance: SNRIs (Duloxetine) and TCAs (Amitriptyline) are staples of pain management because they prevent the reuptake of these modulators, keeping them in the synapse longer to suppress pain signals.

---

4. Summary Table for Board Review

Neurotransmitter	Primary Role	Clinical/Drug Connection
Glutamate	Fast/Slow Excitatory	Ketamine (NMDA antagonist)
Substance P	Excitatory / Neuropeptide	Capsaicin (Depletion)
GABA	Inhibitory (CNS)	Baclofen (GABA-B agonist)
Glycine	Inhibitory (Spinal Cord)	Key in “Gating” mechanism
Norepinephrine	Inhibitory (Descending)	SNRIs / TCAs / Clonidine
Enkephalins	Inhibitory (Opioid)	Opioid Analgesics
Acetylcholine	Autonomic / Neuromuscular	Botox (Inhibits release at NMJ)

---

High-Yield Board “Fast Facts”

• NK-1: The receptor for Substance P.
• NMDA: The receptor responsible for “Wind-up” and opioid-induced hyperalgesia.
• GABA-B: The specific target for Baclofen.
• Substantia Gelatinosa: The area densest in opioid receptors and Substance P.
• Alpha2-Adrenergic: The target for Norepinephrine and Clonidine in the dorsal horn.
• Adenosine: An often-overlooked inhibitory neurotransmitter; caffeine (an adenosine antagonist) can sometimes exacerbate pain or interfere with certain blocks.